Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

Introduction

Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, a targeted anticancer medicine that inhibits fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3.

Pemigatinib is used in selected cancer treatment settings where specific genetic abnormalities are present.

Unlike medicines intended for broad use across many cancer types, pemigatinib is associated with molecularly defined patient populations.

The presence of the appropriate genetic alteration is an important part of determining whether treatment may be suitable.

This page explains the recognized clinical uses of pemigatinib, its mechanism of action, treatment schedules, patient selection requirements and important monitoring considerations.

1. What Is Pemitinib Used For?

Pemitinib is presented on this website as a product containing pemigatinib.

The established reference-product information identifies two important treatment settings in the United States:

FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Pemigatinib is indicated for selected previously treated adults with unresectable locally advanced or metastatic cholangiocarcinoma containing an FGFR2 fusion or other qualifying rearrangement.

FGFR1-rearranged myeloid/lymphoid neoplasms

The U.S. reference-product labeling also includes selected adults with relapsed or refractory myeloid/lymphoid neoplasms involving FGFR1 rearrangement.

These indications are subject to their respective regulatory requirements. Approval and availability may differ between countries.

2. Treatment of FGFR2-Altered Cholangiocarcinoma

Cholangiocarcinoma is a cancer that develops in the bile ducts.

The bile ducts are part of the biliary system, which carries bile from the liver to the digestive tract.

Cholangiocarcinoma may develop in different parts of the biliary system and can present as intrahepatic or extrahepatic disease.

Some tumors contain FGFR2 gene fusions or other qualifying rearrangements.

These genetic changes may contribute to abnormal FGFR signaling and cancer progression.

Pemigatinib inhibits FGFR1, FGFR2 and FGFR3 and can interfere with signaling associated with FGFR2-altered cancer.

Under U.S. reference-product labeling, pemigatinib is used in selected adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma that has the required FGFR2 alteration.

It is not a general treatment for all patients with cholangiocarcinoma.

3. Why Is FGFR2 Testing Important?

Molecular testing is essential when considering pemigatinib for cholangiocarcinoma.

The medicine is intended for patients whose cancer has a qualifying FGFR2 fusion or other rearrangement.

Testing helps identify whether the relevant molecular abnormality is present.

A healthcare professional may use an appropriate validated diagnostic method to evaluate the tumor.

The test result should be interpreted together with the patient’s diagnosis, treatment history and overall clinical condition.

A patient should not assume that pemigatinib is suitable simply because they have been diagnosed with bile duct cancer.

4. Treatment of FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Myeloid/lymphoid neoplasms are uncommon disorders involving abnormal blood-forming cells.

Some of these conditions contain FGFR1 rearrangements.

The genetic alteration can contribute to abnormal cellular signaling and disease development.

Pemigatinib inhibits FGFR signaling and has a U.S.-labeled indication for selected adults with relapsed or refractory myeloid/lymphoid neoplasms involving FGFR1 rearrangement.

The treatment is intended for a specific molecularly defined population.

Patients require evaluation by an appropriate hematology or oncology specialist.

5. What Does Targeted Cancer Treatment Mean?

Targeted cancer treatment focuses on particular biological pathways that contribute to cancer development or progression.

Traditional chemotherapy often affects rapidly dividing cells through broader mechanisms.

Targeted therapies are designed to interfere with selected molecular targets.

Pemigatinib works by inhibiting FGFR1, FGFR2 and FGFR3.

This approach is relevant when a cancer depends on abnormal signaling involving these receptors.

Targeted treatment does not guarantee that a cancer will respond. Individual results vary, and patients require ongoing assessment.

6. How Does Pemigatinib Work?

FGFR proteins are receptor tyrosine kinases involved in cell signaling.

They participate in processes that regulate cellular growth, survival and development.

Certain genetic abnormalities can cause FGFR signaling to become abnormally active.

Pemigatinib inhibits FGFR1, FGFR2 and FGFR3 and interferes with signaling pathways involved in these processes.

The treatment objective is to inhibit abnormal signaling in eligible cancer cells.

The presence of a qualifying molecular abnormality is therefore an important consideration when selecting patients for treatment.

7. Pemigatinib Treatment Schedule for Cholangiocarcinoma

Under U.S. reference-product prescribing information, the recommended schedule for qualifying cholangiocarcinoma is:

  • 13.5 mg once daily.
  • Take the medicine for 14 consecutive days.
  • Follow with seven days without treatment.
  • Repeat in 21-day cycles as prescribed.

The seven-day treatment break is part of the schedule.

Patients should not shorten or extend the treatment cycle independently.

8. Pemigatinib Treatment Schedule for FGFR1-Rearranged Neoplasms

For qualifying FGFR1-rearranged myeloid/lymphoid neoplasms under U.S. reference-product labeling, the recommended schedule is:

  • 13.5 mg once daily.
  • Continue treatment according to the prescribed schedule.
  • Maintain regular medical monitoring.

Unlike the intermittent cholangiocarcinoma schedule, this labeled schedule is continuous.

The correct schedule must be determined by the treating specialist.

9. How Is the Medicine Administered?

The established reference product is an oral tablet.

It may be taken with or without food under U.S. reference-product instructions.

The tablet should be swallowed whole with water.

Patients should not crush, chew, split or dissolve the tablet.

The actual product leaflet and prescription should be checked before administration.

10. Dose Modification and Treatment Interruption

Some patients may require dose modification because of adverse reactions or medical conditions.

For example, hyperphosphatemia and ocular toxicity may require specific management.

Healthcare professionals may recommend treatment interruption, dose reduction or discontinuation depending on the severity of the reaction.

Under U.S. reference-product labeling, patients with severe renal impairment or severe hepatic impairment may require a reduced starting dose.

Dose adjustments should only be made by the treating specialist.

11. Important Monitoring During Treatment

Monitoring is an essential part of pemigatinib treatment.

The treating specialist may recommend:

Blood phosphate testing

Pemigatinib can increase blood phosphate levels. Monitoring helps identify hyperphosphatemia and guide its management.

Eye examinations

Ocular toxicity, including retinal pigment epithelial detachment, is an important safety concern. Eye examinations and OCT are recommended according to the applicable prescribing information.

Kidney and liver assessment

Organ function may influence treatment decisions and dose requirements.

Clinical assessment

The healthcare team should review symptoms, adverse reactions and overall treatment tolerance.

Medication review

Other medicines should be checked for potential interactions, especially those affecting CYP3A enzymes.

12. Possible Benefits of Targeted Treatment

For patients who meet the relevant molecular and clinical requirements, pemigatinib may provide an additional treatment option.

Potential treatment benefits are evaluated through clinical outcomes such as:

  • Tumor response.
  • Duration of response.
  • Disease control.
  • Treatment tolerability.

The degree of benefit varies between patients.

Pemigatinib should not be described as a guaranteed cure or as a treatment that works for every person with an FGFR-related cancer.

13. Common Side Effects During Treatment

Pemigatinib may cause:

  • Hyperphosphatemia.
  • Hair loss.
  • Diarrhea.
  • Nail disorders.
  • Fatigue.
  • Nausea.
  • Constipation.
  • Stomatitis.
  • Dry eyes.
  • Dry mouth.
  • Reduced appetite.
  • Vomiting.
  • Changes in taste.
  • Dry skin.
  • Abdominal discomfort.
  • Joint pain.

The severity and frequency of adverse reactions may vary depending on the indication and patient population.

Patients should discuss persistent or worsening symptoms with their healthcare professional.

14. Serious Safety Considerations

Important risks include hyperphosphatemia, ocular toxicity and embryo-fetal toxicity.

Retinal pigment epithelial detachment is a particularly important eye-related concern.

Patients should promptly report visual changes, including blurred vision, new floaters or flashes of light.

Pregnancy-related precautions should also be discussed before treatment begins.

15. Who May Not Be Suitable for Treatment?

Pemigatinib is not suitable for every patient.

Treatment suitability depends on:

  • The specific cancer diagnosis.
  • Molecular test results.
  • Previous treatment history.
  • Kidney function.
  • Liver function.
  • Existing eye conditions.
  • Other medical conditions.
  • Potential drug interactions.
  • Pregnancy and breastfeeding considerations.

A specialist must assess these factors before treatment.

16. Treatment Is Not Appropriate for Every Cancer

Pemigatinib should not be described as a treatment for all liver cancers, all bile duct cancers or all blood cancers.

Its recognized uses are based on specific molecular abnormalities and regulatory indications.

Patients with other cancer types or without the relevant molecular findings may require different treatment approaches.

A qualified oncologist or hematologist should determine the appropriate treatment.

17. Importance of Following Medical Advice

Patients should attend scheduled appointments and complete recommended laboratory and eye examinations.

They should also report new symptoms and provide their healthcare team with an accurate list of medicines and supplements.

Treatment should not be started, interrupted, restarted or changed without professional instructions.

18. Product and Regulatory Information

Pemitinib is identified on this website as pemigatinib 13.5 mg.

The established reference product PEMAZYRE provides important information about pemigatinib’s clinical uses, dosage and safety.

However, the manufacturer, product formulation, packaging and regulatory status of Pemitinib must be confirmed independently.

Regulatory indications may differ between countries. Healthcare professionals should consult the current prescribing information applicable to the actual product and jurisdiction.

Conclusion

Pemitinib 13.5 mg is presented as a product containing pemigatinib, a targeted FGFR inhibitor.

The established clinical uses of pemigatinib include selected FGFR2-altered cholangiocarcinoma and, under U.S. labeling, selected FGFR1-rearranged myeloid/lymphoid neoplasms.

Treatment requires appropriate molecular testing, specialist prescribing, adherence to the correct treatment schedule and regular safety monitoring.

Patients should always follow their healthcare professional’s instructions and the official prescribing information for the specific product they receive.